Types of Mutations Mutations are changes that occur in the DNA sequence of an organism
In a randomized clinical trial, tesamorelin reduced visceral adipose tissue and liver fat in HIV-infected patients (Stanley et al., JAMA, 2014), and its Phase 3 program (Falutz et al.) established the visceral-fat effect that underpins its FDA approval
Disclosures: Steven Flamm: Nothing to Disclose, Mitchell Shiffman: Bio89: Grant/Research Support, CymaBay: Advisor, CymaBay: Grant/Research Support, Durect: Grant/Research Support, Galectin: Grant/Research Support, Genentech: Grant/Research Support, Genentech: Speaking and Teaching, Gilead: Grant/Research Support, Gilead: Advisor, Gilead: Speaking and Teaching, HepQuant: Grant/Research Support, HepQuant: Advisor, Hamni: Grant/Research Support, High Tide: Grant/Research Support, Interept: Grant/Research Support, Interecept: Speaking and Teaching, Intercept: Advisor, Intra-Sana: Advisor, Intra-Sana: Speaking and Teaching, Ipsen: Advisor, Ipsen: Grant/Research Support, Ipsen: Speaking and Teaching, Madrigal: Grant/Research Support, Madrigal: Speaking and Teaching, Mirum: Grant/Research Support, Pliant: Grant/Research Support, Salix: Grant/Research Support, Salix: Advisor, Viking: Grant/Research Support, Aparna Goel: Nothing to Disclose, Allison Kwong: Nothing to Disclose, Lance Stein: Abbvie: Speaking and Teaching, Gilead: Speaking and Teaching, GSK: Consultant, Intercept: Speaking and Teaching, Intercept: Consultant, Madrigal: Speaking and Teaching, Ipsen: Speaking and Teaching, Ashwini Mehta: Nothing to Disclose, Christophe Moreno: Echosens: Consultant, Surrozen: Consultant, Gilead: Consultant, Julius Clinical: Consultant, Alexandre LOUVET: Glaxo-Smith-Kline: Consultant, AbbVie: Speaking and Teaching, Gilead: Speaking and Teaching, Ipsen: Consultant, Astra-Zeneca: Speaking and Teaching, Sanjaya Satapathy: Gilead Sciences: Grant/Research Support, Durect Pharma: Grant/Research Support, Fibronostics: Grant/Research Support, Novartis: Grant/Research Support, Zydus Pharma: Grant/Research Support, Boehringer Ingelheim: Grant/Research Support, Intercept Pharma: Grant/Research Support, Alexander Kuo: Nothing to Disclose, Daniel Ganger: WCG: Consultant, Costica Aloman: Nothing to Disclose, Amanda Nicoll: Nothing to Disclose, Simone Strasser: Chiesi: Advisor, Roche Diagnostics: Advisor, Roche Therapeutics: Advisor, Norgine: Speaking and Teaching, Abbott Diagnostics: Advisor, CSL Behring: Advisor, Novo Nordisk: Advisor, Astra Zeneca: Advisor, Sirtex: Speaking and Teaching, Eisai: Speaking and Teaching, Mack Mitchell: GlaxoSmithKline: Advisor, Amygdala Neuroscience: Consultant, Parvus Therapeutics: Advisor, HepaTX: Advisor, Durect: Grant/Research Support, Srinivasan Dasarathy: Nothing to Disclose, Edmund Tse: Nothing to Disclose, Mark Thursz: Durect: Consultant, GSK: Consultant, Resolution Tx: Consultant, Intercept: Consultant, Galecto: Consultant, Durect: Consultant, Craig McClain: Novo Nordisk: Grant/Research Support, Intercept Pharmaceuticals: Grant/Research Support, Altimmune: Grant/Research Support, Target Pharma Solutions: Grant/Research Support, NIH: Grant/Research Support, VAMC: Grant/Research Support, William Krebs: DURECT, Incorporated: Independent Contractor, RISE Therapeutics: Independent Contractor, Deborah Scott: Nothing to Disclose, Christina Blevins: Nothing to Disclose, Julie Fergus: Nothing to Disclose, Jim Brown: Durect Corporation: Employee, Norman Sussman: Durect Corporation: Employee, WeiQi Lin: Nothing to Disclose, David Ellis: DURECT Corp.: Employee 1573 SUSTAINING A-KINASE ANCHORING PROTEIN-12 EXPRESSION DURING ALCOHOL EXPOSURE MAINTAINS PKA SIGNALING AND REGULATES STEATOSIS Chandana Thimme Gowda 1 MALLIKARJUNA SIRAGANAHALLI ESHWARAIAH 1 Nirmala Mavila 2 Jiaohong Wang 1 Maria Lauda Tomasi 1 Komal Ramani 2 , 1 Cedars Sinai Medical Centre, 2 Cedars-Sinai Medical Center Background: Alcohol- associated liver disease (ALD) is associated with disrupted lipogenic signaling and fat accumulation in the liver
LET7 interacted strongly with HOP1 TPR1 and HOP1 TPR1/2a , but weakly with HOP1 TPR2a/2b and HOP1 TPR2b
